Madison cancer diagnostics company Exact Sciences Corp. is working on a test that would screen for multiple types of cancer with a single blood draw. It's aiming to help people catch early-stage cancer so it can be treated quickly. For patients who are willing to...
Expanded collaboration to include an additional 20 targets for multi-specific antibody, antibody-drug conjugate, and other biologic candidate discovery and development...
Research on an experimental flu vaccine by Madison-based FluGen continues to expand, with a low dose showing some protection against a mismatched strain, a higher dose producing better immune responses and three new studies targeting older adults and children, groups among those most at risk...
Pyran, Inc., a high-growth company that creates high-performing 5-carbon products made from renewable resources, today announced that it has closed its latest round of fundraising, bringing its total of investments and grants to nearly $4 million....
Madison-based FluGen has been awarded a $11.4 million grant from the Department of Defense to study the ability of its experimental flu vaccine to protect against drifted flu virus strains in older adults, the company said Thursday....
Nimble Therapeutics and RayzeBio today announced the companies have entered a strategic collaboration to discover and develop novel peptide-based radiopharmaceuticals for treatment of cancer....
The latest edition of “The Wisconsin Portfolio” shows more than $483 million was raised by the state’s early stage companies in 2020, a record for any calendar year in Wisconsin but still not on par with other Midwest states....
Danaher has entered into a definitive agreement to acquire privately-held Aldevron, for a cash purchase price of approximately $9.6 billion. ...
Today, the U.S. Food and Drug Administration approved StrataGraft for the treatment of adult patients with thermal burns containing intact dermal elements (remaining deep skin layers) for which surgical intervention is clinically indicated....
New guidelines have moved the recommended age to start getting screened for colon cancer from age 50 to 45, which could also have major implications for Madison-based Exact Sciences Corp., the biotech company behind the at-home colon cancer screening test Cologuard....